Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast

Oruka Therapeutics (NASDAQ:ORKA) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Oruka Therapeutics and Alpha Teknova, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	7	2	3.22
Alpha Teknova	0	1	2	0	2.67

Oruka Therapeutics presently has a consensus price target of $39.86, indicating a potential upside of 256.50%. Alpha Teknova has a consensus price target of $8.50, indicating a potential upside of 2.66%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than Alpha Teknova.

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 15.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Oruka Therapeutics and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-24.96%	-21.22%
Alpha Teknova	-87.17%	-35.30%	-24.52%

Risk and Volatility

Oruka Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.

Earnings & Valuation

This table compares Oruka Therapeutics and Alpha Teknova”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-1.79
Alpha Teknova	$36.68 million	12.03	-$36.78 million	($0.74)	-11.19

Oruka Therapeutics has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Oruka Therapeutics beats Alpha Teknova on 12 of the 14 factors compared between the two stocks.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.